Repeated measurements in patients presenting with ST-segment elevation myocardial infarction of Advanced Glycation Endproducts by skin autofluorescence and serum analysis: a pilot study.
- Conditions
- ''ST segment elevation myocardial infarction'' and ''heart attack''10028593
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 40
- Men and women, aged from 18 year, capable of understanding the study content of and willing to provide written informed consent at admission to the hospital.
- Diagnosis of STEMI, according to the guidelines of the European Society of Cardiology (ESC) 2008. The diagnosis is defined as a history of chest pain / discomfort lasting for
10 - 20 minutes or more (not responding fully to nitroglycerine) with persistent ST segment elevation and elevated markers of myocardial necrosis. Other causes of chest pain / discomfort must be ruled out by the cardiologist.
- Symptom duration <6h.
- Admission for an ACS <6 months
- Clinically significant renal disturbance (GFR (MDRD) <= 30 mL/min/1.73m2) or known renal disease
- Severe inflammatory or current malignant disease
- Darkly coloured skin
- Auto-immune / connective tissue disease
- Aorta dissection
- Comatose at admission to the CCU
Study & Design
- Study Type
- Observational invasive
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method <p>The primary endpoints are serial measurements of a) skin AF by the AGE reader®<br /><br>and<br /><br>b) value of AGEs as measured in serum. Furthermore, cardiac enzymes levels will<br /><br>be assessed repeatedly to determine the area under the curve for estimation of<br /><br>the infarct size.</p><br>
- Secondary Outcome Measures
Name Time Method <p>Secundary study parameters/outcome are not applicable</p><br>